IL5 and asthma: We found that treatment with anti‐IgE, anti‐IL‐5/R and anti‐IL‐4R while improving asthma outcomes, also all significantly reduced the symptoms of CRSwNP measured by SNOT‐20, supporting the “one airway concept” that assumes similar pathomechanisms in CRSwNP and asthma.7